» Articles » PMID: 23764370

Delta Opioid Receptors in Brain Function and Diseases

Overview
Journal Pharmacol Ther
Specialty Pharmacology
Date 2013 Jun 15
PMID 23764370
Citations 58
Authors
Affiliations
Soon will be listed here.
Abstract

Evidence that the delta opioid receptor (DOR) is an attractive target for the treatment of brain disorders has strengthened in recent years. This receptor is broadly expressed in the brain, binds endogenous opioid peptides, and shows as functional profile highly distinct from those of mu and kappa opioid receptors. Our knowledge of DOR function has enormously progressed from in vivo studies using pharmacological tools and genetic approaches. The important role of this receptor in reducing chronic pain has been extensively overviewed; therefore this review focuses on facets of delta receptor activity relevant to psychiatric and other neurological disorders. Beneficial effects of DOR agonists are now well established in the context of emotional responses and mood disorders. DOR activation also regulates drug reward, inhibitory controls and learning processes, but whether delta compounds may represent useful drugs in the treatment of drug abuse remains open. Epileptogenic and locomotor-stimulating effects of delta agonists appear drug-dependent, and the possibility of biased agonism at DOR for these effects is worthwhile further investigations to increase benefit/risk ratio of delta therapies. Neuroprotective effects of DOR activity represent a forthcoming research area. Future developments in DOR research will benefit from in-depth investigations of DOR function at cellular and circuit levels.

Citing Articles

Recommended Opioid Receptor Tool Compounds: Comparative for Receptor Selectivity Profiles and for Pharmacological Antinociceptive Profiles.

Tran L, Freeman K, Lunzer M, Portoghese P, Haskell-Luevano C ACS Pharmacol Transl Sci. 2025; 8(1):225-244.

PMID: 39816790 PMC: 11729433. DOI: 10.1021/acsptsci.4c00604.


Delta opioid receptors engage multiple signaling cascades to differentially modulate prefrontal GABA release with input and target specificity.

Alexander R, Bender K bioRxiv. 2024; .

PMID: 39149233 PMC: 11326311. DOI: 10.1101/2024.08.08.607246.


Opioid modulation of prefrontal cortex cells and circuits.

Cole R, Moussawi K, Joffe M Neuropharmacology. 2024; 248:109891.

PMID: 38417545 PMC: 10939756. DOI: 10.1016/j.neuropharm.2024.109891.


μ-opioid receptor agonists and psychedelics: pharmacological opportunities and challenges.

Salinsky L, Merritt C, Zamora J, Giacomini J, Anastasio N, Cunningham K Front Pharmacol. 2023; 14:1239159.

PMID: 37886127 PMC: 10598667. DOI: 10.3389/fphar.2023.1239159.


Tryptophan Substitution in CJ-15,208 ([Phe-D-Pro-Phe-Trp]) Introduces δ-Opioid Receptor Antagonism, Preventing Antinociceptive Tolerance and Stress-Induced Reinstatement of Extinguished Cocaine-Conditioned Place Preference.

Scherrer K, Eans S, Medina J, Senadheera S, Khaliq T, Murray T Pharmaceuticals (Basel). 2023; 16(9).

PMID: 37765026 PMC: 10535824. DOI: 10.3390/ph16091218.


References
1.
Jutkiewicz E, Kaminsky S, Rice K, Traynor J, Woods J . Differential behavioral tolerance to the delta-opioid agonist SNC80 ([(+)-4-[(alphaR)-alpha-[(2S,5R)-2,5-dimethyl-4-(2-propenyl)-1-piperazinyl]-(3-methoxyphenyl)methyl]-N,N-diethylbenzamide) in Sprague-Dawley rats. J Pharmacol Exp Ther. 2005; 315(1):414-22. PMC: 1307500. DOI: 10.1124/jpet.105.088831. View

2.
Chao D, Balboni G, Lazarus L, Salvadori S, Xia Y . Na+ mechanism of delta-opioid receptor induced protection from anoxic K+ leakage in the cortex. Cell Mol Life Sci. 2009; 66(6):1105-15. PMC: 2704459. DOI: 10.1007/s00018-009-8759-5. View

3.
Randall-Thompson J, Pescatore K, Unterwald E . A role for delta opioid receptors in the central nucleus of the amygdala in anxiety-like behaviors. Psychopharmacology (Berl). 2010; 212(4):585-95. PMC: 3990196. DOI: 10.1007/s00213-010-1980-y. View

4.
Crist R, Ambrose-Lanci L, Vaswani M, Clarke T, Zeng A, Yuan C . Case-control association analysis of polymorphisms in the δ-opioid receptor, OPRD1, with cocaine and opioid addicted populations. Drug Alcohol Depend. 2012; 127(1-3):122-8. PMC: 3509227. DOI: 10.1016/j.drugalcdep.2012.06.023. View

5.
Nozaki C, Le Bourdonnec B, Reiss D, Windh R, Little P, Dolle R . δ-Opioid mechanisms for ADL5747 and ADL5859 effects in mice: analgesia, locomotion, and receptor internalization. J Pharmacol Exp Ther. 2012; 342(3):799-807. PMC: 3422521. DOI: 10.1124/jpet.111.188987. View